Bachmann G, Steffen R, Glück R, Wegmann A, Schär M
Schweiz Med Wochenschr. 1985 Jun 22;115(25):863-5.
An economical, highly purified and concentrated duck embryo rabies vaccine (PDEV) was investigated in relation to pre-exposure rabies prophylaxis. The vaccine was injected subcutaneously according to the then prescribed scheme for human diploid cell rabies vaccines (HDCV). Additionally, a third dose was given on day 120. Serum anti-rabies antibody levels were determined on days 0, 56, 120, und 170. On day 56 all volunteers showed an anti-rabies antibody level of at least 1.0 IU/ml, indicating that PDEV is sufficiently immunogenic to allow its use according to the pre-exposure schedules for HDCV. Some rather low titers noted on day 120 indicate that an early booster dose or a third primary immunization dose is justified, as recently recommended by the WHO.
对一种经济、高度纯化且浓缩的鸭胚狂犬病疫苗(PDEV)进行了暴露前狂犬病预防方面的研究。该疫苗按照当时规定的人二倍体细胞狂犬病疫苗(HDCV)方案皮下注射。此外,在第120天给予第三剂。在第0、56、120和170天测定血清抗狂犬病抗体水平。在第56天,所有志愿者的抗狂犬病抗体水平至少为1.0 IU/ml,表明PDEV具有足够的免疫原性,可根据HDCV的暴露前方案使用。第120天观察到的一些较低滴度表明,按照世界卫生组织最近的建议,早期加强剂量或第三次初次免疫剂量是合理的。